Six proposals were not heard during the Coordination and Maintenance committee meeting.
The Coordination and Maintenance Committee Meeting was held March 9 – 10, 2021. The meeting began with discussion of the ICD-10-PCS topics. There were six proposals that were not discussed during the meeting which were therapeutic administration of drugs/substances. This article will review the six proposals. Remember that all comments for all procedure topics are due April 9, 2021. The comments should be sent to ICDProcedureCodeRequest@cms.hhs.gov.
The first proposal was for the administration of Amivantamab which is used to treat epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer with Exon20 insertions. The five-year survival rate is 8 percent with this type of cancer. This drug is a fully human bispecific antibody that binds to the extracellular domains of the epidermal growth factor and mesenchymal epithelial transition (MET). It is administered on a 28-day cycle on an outpatient basis. Patients may need to be administered if admitted for other complications of the disease. This drug has been designated as a breakthrough therapy and is currently working through clinical trials.
The second proposal is for the administration of Ciltacabtagene Autoleucel which is a B-cell maturation Antigen Directed CAR T-cell Therapy. This drug treats relapsed/refractory multiple myeloma. It takes approximately 57 days from registration to complete the initial round of therapy. There is a PCS code for CAR T-cell therapy, but not specific to this type of therapy.
The third proposal is ENSPRYNG (satralizumab mwge) which is a humanized IgG2 monoclonal antibody which is used for treating Neuromyelitis Optica Spectrum Disorder (NMOSD). Patients with this disorder relapsed 60% within one year and 90 percent within three years. These patients required wheelchairs (50 percent) and could be functionally blind (62percent). In the study, there was significant reduction in relapse. This medication is given subcutaneously as an inpatient or outpatient. After a loading dose, the medication is administered every four weeks.
The fourth proposal is administration of Trilaciclib which is a myelopreservation therapy. The goal of this therapy is to mitigate chemotherapy induced myelosuppression in extensive non-small cell lung cancer patients. Trilaciclib has been granted FDA breakthrough therapy status. This medication is administered intravenously or via central line. Patients are treated with four cycles of 21-day therapy. The patient is given chemotherapy with Trilaciclib days 1 – 3 followed by 18 days treatment free. One inpatient admission is expected, but the medication can be administered as an inpatient or outpatient.
The fifth proposal is administration of ZEPZELCA (lurbinectedin) which is a transcription inhibitor for patients with metastatic small cell lung carcinoma. This is a second line option whose cancer has progressed while on traditional chemotherapy. This medication has been approved by the Federal Drug Administration (FDA). The schedule for this medication is every 21 days. It can be administered on an inpatient or outpatient basis.
The last proposal is the transfusion of pathogen reduced cryoprecipitated fibrinogen complex (PRCFC) which is used to treat massive bleeding when patient is fibrinogen deficient. This substance is not the same as the usual cryoprecipitate. This substance has been approved by the FDA and was awarded breakthrough device designation. PRCFC is treated by INTERCEPT Blood System which inactivates pathogens to reduce transfusion transmitted infections (TTI). This product has a five-day at room temperature shelf-life.
These six drugs/products have requested New Technology Add-On Payment (NTAP) which provides additional reimbursement to the Medicare-Severity Diagnosis Related Group (MS-DRG). In proposed rule for Inpatient Prospective Payment System (IPPS) FY22, a preliminary recommendation will be published. These procedure codes are being considered for FY22 which begins Oct. 1, 2021.
Programming Note: Listen to Laurie Johnson report this story live today during Talk Ten Tuesdays, 10 a.m. Eastern.
The Coordination and Maintenance (C&M) Committee meeting was held on Sept. 12 and 13. The meeting began with the procedure proposals, which were followed by
The next Coordination and Maintenance (C&M) Committee meeting will be held on Sept. 12 and 13 . This meeting will be virtual, and you must
Please log in to your account to comment on this article.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
Copyright © 2024 ICD10monitor. Powered by MedLearn Media.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
